Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial

Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-03, Vol.21 (6), p.1487-1492
Main Authors: Tuccinardi, Dario, Farr, Olivia M., Upadhyay, Jagriti, Oussaada, Sabrina M., Mathew, Hannah, Paschou, Stavroula A., Perakakis, Nikolaos, Koniaris, Anastasia, Kelesidis, Theodoros, Mantzoros, Christos S.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus, we investigated how lorcaserin administration may alter cardiovascular disease risk, either independently or through changes in body weight, measuring, for the first time, lipid particle quantification, lipid peroxidation, appetite-regulating hormones and the mRNA expression of 5-HT2C receptor . Forty-eight obese subjects were enrolled in this 6-month-long, randomized (1:1), placebo-controlled, double-blinded clinical trial. Lorcaserin treatment reduced fat mass (p
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13655